Congress may give U.S. regulators greater oversight of pharmacy benefit managers amid Federal Trade Commission concern that these entities might be using anti-competitive business practices to inflate drug prices.
"When PBMs were first created, they were beneficial to the entire health care system. There was more than a dozen large PBMs across the country, all competing with each other to provide clear details about costs, fees, and rebates to pharmacies and patients," said Rep. James Comer, R-Kentucky, and chair of the House Oversight and Accountability Committee.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Maydeen Merino
Maydeen Merino is a regulatory reporter, covering the DOJ, FTC, SEC and EPA. She can be reached at [email protected].
